<div><p><b>Background: </b>Physical frailty and sarcopenia are related but not fully overlapping, and links to outcomes and health care utilization in liver cirrhosis. Physical frailty may be assessed with Liver Frailty Index (LFI) or Short Performance Physical Battery (SPPB), and sarcopenia is typically assessed by measuring muscle size using imaging.</p>

<div><p><strong><b>Background:</strong> </b></p>

<div><p><b>Background:</p> </b><p>Lubiprostone has been shown to improve intestinal permeability. We aimed to assess the safety and efficacy of lubiprostone in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).</p>

<div><p><b>Background: </b>Primary sclerosing cholangitis (PSC) is marked by inflammation and progressive biliary fibrosis, which can lead to cirrhosis and its complications. Cholangiocytes activated by transforming growth factor-𝛽 (TGF𝛽) signal to immune cells and activate hepatic myofibroblasts to deposit the extracellular matrix. Our previous data suggest that TGF𝛽-mediated transcriptomic changes in cholangiocytes may occur through runt-related transcription factors (RUNX).

<div><p><strong>Background</strong>: Systemic inflammation is known as a major role in pathogenesis of acute-on-chronic liver failure (ACLF) from cross-sectional studies, but its detailed impacts on the dynamic trajectory of this disease from the absence of organ dysfunction (OD) to onset of OD, organ failure (OF) and eventual ACLF remains poorly understood due to challenges in collecting data and samples from individuals. Multinomial and ordinal regression analyses are useful tools to circumvent the limitation intrinsic to cross-sectional studies in cirrhosis.

<div><p><b>Background: </b>New therapeutic alternatives to corticosteroids in severe alcohol-associated hepatitis (SAH) is unmet need. Fecal microbiota transplantation (FMT) has been proposed as it targets well-established pathophysiological pathway but, data is scarce and many unanswered questions remain. One of the principal tools for personalized management of SAH is selection of patients whose potential to benefit from FMT is increased based on their pre-FMT gut-microbiome analysis.</p>

<div><p><b>Background:<span data-contrast="auto" xml:lang="EN-CA" lang="EN-CA" class="TextRun SCXW165043786 BCX0"> </b><span class="NormalTextRun SCXW165043786 BCX0">Multimodal treatment for pediatric liver tumors</span><span class="NormalTextRun SCXW165043786 BCX0">, including indications for transplantation,</span><span class="NormalTextRun SCXW165043786 BCX0"> has evolved over the last several</span><span class="NormalTextRun SCXW165043786 BCX0&q

<div><p><b>Background: </b>Immune checkpoints (CTLA4 &amp; PD1) are inhibitory pathways that block aberrant immune activity and maintain self-tolerance. Tumors co-opt these checkpoints to avoid immune destruction. Immune Checkpoint Inhibitors (ICIs) activate immune cells and restore their tumoricidal potential, making them highly efficacious cancer therapies.

<div><p><b>Background:</p> </b><div><p><span lang="EN-US">Despite recent developments, it is still very difficult to differentiate hepatocellular carcinoma (HCC) from intrahepatic cholangiocarcinoma (iCCA). Clinically available methods such as CT, MRI, and contrast-enhanced ultrasound require the highest level of investigator experience to reliably differentiate between HCC and iCCA.

<div><p><b>Background:</p> </b><p style="font-weight: 400;">Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) has extremely high prevalence in the US and globally with increasing incidence of morbidity and mortality in the population.